Research programme: anticancer therapeutics - Plexxikon/Genentech
Alternative Names: PLX 152; PLX 225; PLX 391; PLX 628; PLX 630; PLX 762Latest Information Update: 07 Jul 2022
At a glance
- Originator Plexxikon
- Developer Genentech; Plexxikon
- Class Small molecules
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 06 Jul 2022 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 21 May 2003 Preclinical trials in Cancer in USA (unspecified route)